| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Dilshani W N Dissanayake, Robert Mason, Charles A Marsde. Sensory gating, cannabinoids and schizophrenia. Neuropharmacology. vol 67. 2013-11-04. PMID:23154301. |
furthermore, cannabinoids disrupt sensory gating in animals and humans which supports the hypothesis that the disruption of sensory gating by alterations in the endocannabinoid system is a significant factor in the etiology of schizophrenia. |
2013-11-04 |
2023-08-12 |
Not clear |
| Dilshani W N Dissanayake, Robert Mason, Charles A Marsde. Sensory gating, cannabinoids and schizophrenia. Neuropharmacology. vol 67. 2013-11-04. PMID:23154301. |
based on the above hypothesis this article reviews the sensory gating process in relation to the auditory conditioning-test paradigm with an emphasis on its association with the endocannabinoid system and schizophrenia. |
2013-11-04 |
2023-08-12 |
Not clear |
| Leonora E Long, Rose Chesworth, Xu-Feng Huang, Iain S McGregor, Jonathon C Arnold, Tim Kar. Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence. The international journal of neuropsychopharmacology. vol 16. issue 1. 2013-10-17. PMID:22226049. |
to test whether the schizophrenia candidate gene neuregulin 1 (nrg1) modulates the effects of cannabinoids in adolescence, we tested male adolescent heterozygous transmembrane domain nrg1 mutant (nrg1 tm het) mice and wild type-like littermates (wt) for their neurobehavioural response to repeated Δ(9)-tetrahydrocannabinol (thc, 10 mg/kg i.p. |
2013-10-17 |
2023-08-12 |
mouse |
| Alain Dervaux, Marie-Chantal Bourdel, Xavier Laqueille, Marie-Odile Kreb. Neurological soft signs in non-psychotic patients with cannabis dependence. Addiction biology. vol 18. issue 2. 2013-09-18. PMID:21054691. |
these results suggest that cannabinoids interact with the brain networks underlying nss, known to be altered in schizophrenia. |
2013-09-18 |
2023-08-12 |
human |
| Victoria S Dalton, Mathieu Verdurand, Adam Walker, Deborah M Hodgson, Katerina Zavitsano. Synergistic Effect between Maternal Infection and Adolescent Cannabinoid Exposure on Serotonin 5HT1A Receptor Binding in the Hippocampus: Testing the "Two Hit" Hypothesis for the Development of Schizophrenia. ISRN psychiatry. vol 2012. 2013-06-06. PMID:23738203. |
synergistic effect between maternal infection and adolescent cannabinoid exposure on serotonin 5ht1a receptor binding in the hippocampus: testing the "two hit" hypothesis for the development of schizophrenia. |
2013-06-06 |
2023-08-12 |
rat |
| Victoria S Dalton, Mathieu Verdurand, Adam Walker, Deborah M Hodgson, Katerina Zavitsano. Synergistic Effect between Maternal Infection and Adolescent Cannabinoid Exposure on Serotonin 5HT1A Receptor Binding in the Hippocampus: Testing the "Two Hit" Hypothesis for the Development of Schizophrenia. ISRN psychiatry. vol 2012. 2013-06-06. PMID:23738203. |
our results suggest a synergistic effect of prenatal infection and adolescent cannabinoid exposure on the integrity of the serotoninergic system in the hippocampus that may provide the neurochemical substrate for abnormal hippocampal-related functions relevant to schizophrenia. |
2013-06-06 |
2023-08-12 |
rat |
| Serena Deian. Medical use of cannabis. Cannabidiol: a new light for schizophrenia? Drug testing and analysis. vol 5. issue 1. 2013-06-03. PMID:23109356. |
given the need to reduce the side effects of marketed antipsychotics, and their weak efficacy on some schizophrenic symptoms, cannabinoids have been suggested as a possible alternative treatment for schizophrenia. |
2013-06-03 |
2023-08-12 |
Not clear |
| Serena Deian. Medical use of cannabis. Cannabidiol: a new light for schizophrenia? Drug testing and analysis. vol 5. issue 1. 2013-06-03. PMID:23109356. |
behavioural and neurochemical models suggest that cbd has a pharmacological profile similar to that of atypical anti-psychotic drugs and a clinical trial reported that this cannabinoid is a well-tolerated alternative treatment for schizophrenia. |
2013-06-03 |
2023-08-12 |
Not clear |
| Rodrigo Ferretjans, Fabrício A Moreira, Antônio L Teixeira, João V Salgad. The endocannabinoid system and its role in schizophrenia: a systematic review of the literature. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). vol 34 Suppl 2. 2013-05-17. PMID:23429846. |
the endocannabinoid system and its role in schizophrenia: a systematic review of the literature. |
2013-05-17 |
2023-08-12 |
Not clear |
| K A Gleason, S G Birnbaum, A Shukla, S Ghos. Susceptibility of the adolescent brain to cannabinoids: long-term hippocampal effects and relevance to schizophrenia. Translational psychiatry. vol 2. 2013-05-16. PMID:23188199. |
susceptibility of the adolescent brain to cannabinoids: long-term hippocampal effects and relevance to schizophrenia. |
2013-05-16 |
2023-08-12 |
mouse |
| E Zamberletti, F Piscitelli, F Cadeddu, T Rubino, W Fratta, P Fadda, V Di Marzo, D Parolar. Chronic blockade of CB(1) receptors reverses startle gating deficits and associated neurochemical alterations in rats reared in isolation. British journal of pharmacology. vol 167. issue 8. 2013-05-06. PMID:22762735. |
pharmacological interventions aimed at restoring the endocannabinoid system functionality have been proposed as potential tools in the treatment of schizophrenia. |
2013-05-06 |
2023-08-12 |
rat |
| Miriam Melis, Marco Pisti. Hub and switches: endocannabinoid signalling in midbrain dopamine neurons. Philosophical transactions of the Royal Society of London. Series B, Biological sciences. vol 367. issue 1607. 2013-04-08. PMID:23108546. |
because dysfunctions of the dopamine system underlie diverse neuropsychiatric disorders, including schizophrenia and drug addiction, the importance of better understanding the correlation between an unbalanced endocannabinoid signal and the dopamine system is even greater. |
2013-04-08 |
2023-08-12 |
Not clear |
| J C Arnold, A A Boucher, T Kar. The yin and yang of cannabis-induced psychosis: the actions of Δ(9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716133. |
we will also review novel rodent models used to address genetic vulnerability to cannabis-induced schizophrenia and show that specific genes are being uncovered that modulate cannabinoid action (e.g. |
2013-03-25 |
2023-08-12 |
Not clear |
| Jurgen Gallinat, Johannes Rentzsch, Patrik Rose. Neurophysiological effects of cannabinoids: implications for psychosis research. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716142. |
in this overview, we report on human clinical and experimental studies investigating the acute and chronic effects of cannabinoids on specific neurophysiological measures, i.e., the p50 suppression, the mismatch negativity, and the p300 potential, that consistently showed characteristic abnormalities in schizophrenia. |
2013-03-25 |
2023-08-12 |
human |
| Jurgen Gallinat, Johannes Rentzsch, Patrik Rose. Neurophysiological effects of cannabinoids: implications for psychosis research. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716142. |
based on the results, we discuss some explanations on the putative mechanisms involving the endocannabinoid system and its interactions with other neuromodulators that might form the neural substrates underlying cannabis-induced cognitive impairments and help understand the neurobiology underpinning the development of cognitive deficits in schizophrenia. |
2013-03-25 |
2023-08-12 |
human |
| Raquel Levin, Valeria Almeida, Fernanda Fiel Peres, Mariana Bendlin Calzavara, Neide Derci da Silva, Mayra Akimi Suiama, Suzy Tamie Niigaki, Antonio Waldo Zuardi, Jaime Eduardo Cecilio Hallak, Jose Alexandre Crippa, Vanessa Costhek Abíli. Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716146. |
clinical and neurobiological findings suggest that cannabinoids and their receptors are implicated in schizophrenia. |
2013-03-25 |
2023-08-12 |
rat |
| F Markus Lewek. Anandamide dysfunction in prodromal and established psychosis. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716147. |
based on these observations, there is growing interest in the role of the endogenous cannabinoid system (ecb system) - the point of action for psychoactive cannabinoids - in psychiatric disorders and schizophrenia in particular. |
2013-03-25 |
2023-08-12 |
Not clear |
| F Markus Lewek. Anandamide dysfunction in prodromal and established psychosis. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716147. |
it has been hypothesized nearly two decades ago that the ecb system may play a pathophysiological role in schizophrenia either in terms of an endogenous malfunction of the system itself and/or of a secondary malfunction as a result of the use of exogenous cannabinoids like Δ(9)-tetrahydrocannabinol, the major psychoactive phytocannabinoid in cannabis sativa. |
2013-03-25 |
2023-08-12 |
Not clear |
| Aviv Segev, Shaul Lev-Ra. Neurocognitive functioning and cannabis use in schizophrenia. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716156. |
the effects of cannabis are mediated through the endocannabinoid system, which is a major regulator of neurotransmission and may be disturbed in schizophrenia. |
2013-03-25 |
2023-08-12 |
Not clear |
| Erica Zamberletti, Tiziana Rubino, Daniela Parolar. The endocannabinoid system and schizophrenia: integration of evidence. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716159. |
the endocannabinoid system and schizophrenia: integration of evidence. |
2013-03-25 |
2023-08-12 |
human |